We are seeing a shift in the political will to decriminalise cannabis, not least in the US and Germany, where significant steps in legislature are being considered. This will also have important effects on the field of medical cannabis, which has already seen a tectonic shift towards a more general acceptance in recent years. Danish biopharma company DanCann Pharma, with one of the world's most modern facilities for manufacturing medical cannabis, is one of the top European players in this field. To inch closer to profitability, the company is now carrying out a rights issue of 28.5 million DKK that ends on November 11th.

Read the article at biostock.se:


This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/en/


(c) 2022 Cision. All rights reserved., source Press Releases - English